32240 Baseline characteristics and comorbid conditions in patients with moderate-to-severe plaque psoriasis enrolled in the Psoriasis Study of Health Outcomes (PSoHO)

Abstract

Aim: This interim analysis of the Psoriasis Study of Health Outcomes (PSoHO) describes the baseline comorbidities of the first 700 enrolled patients to improve our understanding of treatment patterns in the real-world setting. Methods: PSoHO is a 3-year international, prospective, multicenter, noninterventional cohort study comparing the clinical effectiveness of antiinterleukin (IL)-17A biologics versus other biologics in treating PsO. Patients (≥18 years) had moderate-to-severe PsO and initiated/switched biologics during routine medical care. Physicians recorded patients’ baseline comorbidities from a prespecified list. Baseline comorbidity rates by treatment group were analyzed using Fisher exact test. Results: This interim cohort (n = 700) was 57.7% male, with a mean baseline (standard deviation) age of 46.2 (13.7) years, Body Mass Index of 29.5 (6.9), Psoriasis Area and Severity Index of 14.8 (8.6) and Dermatology Life Quality Index of 11.9 (7.5). The mean number of comorbidities was 1.3 (1.8) with 59.2% (181/306) of the anti-IL-17A cohort and 59.4% (234/394) of the other biologics cohort reporting comorbidities. For the anti-IL-17A and other biologics cohorts, the most frequent comorbidities were psoriatic arthritis (25.2% [77/306] and 19.5% [77/394]), hypertension (25.5% [78/306] and 25.1% [99/394]), dyslipidemia (19.3% [59/306] and 17.0% [67/394]) and diabetes (8.8% [27/306] and 10.7% [42/394]), respectively. No significant differences were observed between cohorts for all reported comorbidities. Conclusion: This interim analysis suggests that biologic-treated patients with PsO have more heterogenous disease and a higher comorbid disease burden in the real world than clinical trial populations, including conditions that usually exclude clinical trial enrollment.